Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep - Phase II study for eftilagimod alpha in COVID-19 advances (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, ann...read more

Immutep Quarterly Activities Report & Appendix 4C (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, pro...read more

Immutep - Ulcerative Colitis Phase II Study of GSK2831781 Discontinued (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, adv...read more

Immutep - Recruitment of head & neck cancer patients completed for ph2 (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has enrolled and safely dosed t...read more

Immutep - Resignation and Appointment of Joint Company Secretary (ASX:IMM)

ASX and NASDAQ listed biotechnology company Immutep Limited (“Immutep“ or the “Company“), advises that Mr Tom Bloomfield has resigned as the joint Company Secretary of the Co...read more

Immutep - Change in substantial holding (ASX:IMM)

To view the Notice of change of interests of substantial holder, download the attached PDF.

Immutep - Appendix 2A (ASX:IMM)

To view the Application for quotation of +securities, download the attached PDF.

Immutep - Change in substantial holding (ASX:IMM)

To view the Notice of change of interests of substantial holder, download the attached PDF.

Immutep - Change in substantial holding (ASX:IMM)

To view the notice of change of interests of substantial holder, download the attached PDF.

Immutep granted US patent for eftilagimod alpha with a PD-1 (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is ...read more